Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy

Oncolytic virotherapy, the selective killing of tumor cells by oncolytic viruses (OVs), has emerged as a promising avenue of anticancer research. We have previously shown that KM100, a Herpes simplex virus type-1 (HSV) deficient for infected cell protein 0 (ICP0), possesses substantial oncolytic pro...

Full description

Saved in:
Bibliographic Details
Main Authors: Sobol, Paul T, Boudreau, Jeanette E, Stephenson, Kyle, Wan, Yonghong, Lichty, Brian D, Mossman, Karen L
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2011
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3034857/
https://ncbi.nlm.nih.gov/pubmed/21119618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2010.264
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items